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Updated guidance from NICE on implantable defibrillators: does it work in real life? 
The National Institute for Health and Clinical Excellence (NICE) was set up (under a slightly different 
name) in 1999 as a public body independent of the UK Government, with the remit to reduce the 
variation in the availability and quality of NHS treatments and care in England. It has published 
numerous clinical guidelines and technology appraisals, and is well respected around the world for 
its robust and transparent assessment of the evidence, and the opportunity it gives relevant 
stakeholders to input to the assessment process. In June 2014 it published its 314
th
 technology 
appraisal (TA314),
1
 updating its guidance on the use of implantable defibrillator (ICD) technology, 
and merging this with an update on its guidance on the use of cardiac resynchronisation technology 
(CRT).  
In the absence of new trial evidence, TA314 made the same recommendations for the secondary 
prevention of sudden cardiac death as in its previous guidance (TA95, January 2006):  ICDs continued 
to be recommended for people who had survived a cardiac arrest caused by either ventricular 
tachycardia (VT) or ventricular fibrillation, or had spontaneous sustained VT causing syncope or 
significant haemodynamic compromise, or had sustained VT without syncope or cardiac arrest and a 
left ventricular ejection fraction (LVEF) ≤ 35% and symptoms no worse than NYHA Class III. Those 
with a familial cardiac condition with a high risk of sudden death (such as long QT Syndrome, 
Brugada Syndrome, hypertrophic cardiomyopathy, or arrhythmogenic right ventricular dysplasia) or 
surgically repaired congenital heart disease also continued to be included in the recommendations 
as candidates for an ICD.   
In contrast, there were major changes in the guidance related to the primary prevention of sudden 
death. The guidance was no longer limited to ischaemic cardiomyopathy, and the use of Holter 
monitoring and electrophysiological studies to test the inducibility of VT disappeared. Emphasis was 
now focused on all patients with an EF ≤ 35%, and eligibility for an ICD or CRT-D/CRT-P implantation 
was largely determined by QRS duration and morphology, and by NYHA class. A simple Table (Table 
1) was provided to illustrate which technologies were optimal for which patients based on these 
characteristics. 
This approach was based on individual patient data (IPD) synthesised by network meta-analysis from 
13 randomised trials (12 638 patients) provided by medical technology companies – representing 
95% of patients enrolled in randomised controlled trials of such implantable devices.
2
  These data 
provided estimates for expected relative benefit conditional upon multiple patient characteristics, 
and likely cost-effectiveness based on the absolute levels of mortality, hospitalisation and quality of 
life reported in the trials. NICE decided to accept the importance of QRS duration and left bundle 
branch block, but dropped the evidence that gender and age affected the relative benefit.  
Cubbon et al, in this edition of Heart,
3
 set out to determine how well the new NICE guidance works 
in real life – does it identify the individuals with increased risk of sudden cardiac death? They 
constructed a historical cohort of 1091 patients with heart failure with reduced ejection fraction 
(HFREF) that had been prospectively identified in several cardiology outpatient departments in the 
UK between June 2006 and December 2011, and followed up for a mean of 3.7 years. The mean age 
of these patients was 68 and 74% were male, 63% had ischaemic heart disease and 26% were 
diabetic. 47% had a QRS duration of at least 120 ms (of these: 29% had LBBB, 6% RBBB and 12% a 
non-specific morphology). The use of heart failure drug therapy was high - 89% were on an ACE 
inhibitor or angiotensin receptor blocker, 81% were on a beta-adrenoreceptor blocker, and 41% on a 
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mineralocorticoid receptor antagonist - and 31% had an implantable device (3% ICD alone, 18% CRT-
P, and 9% CRT-D). 344 patient died or had an appropriate ICD shock during the follow-up period (9 
events per 100 person years), and 78 of these events (2 events per 100 person years) were classified 
as sudden cardiac deaths (SCD) including 50 deaths and 28 appropriate ICD shocks (8 for VF, 20 for 
VT with a median programmed threshold for ICD shock of 188bpm).   
Within this hospital-based cohort, 31% fulfilled the specific NICE criteria for an ICD given in Table 1 
(i.e. QRS duration ≥120ms, NYHA Class 1-3, and LVEF ≤ 35%). Such patients had a substantially 
increase risk of SCD (Hazard ratio [HR] 2.5 (95% confidence interval 1.6-3.9) p<0.001) and a 
somewhat increased risk also of progressive pump failure death (HR 1.6 (1.1-2.3) p=0.02), and non-
cardiovascular death (HR 1.5 (1.1-2.2) p=0.027). This is perhaps not surprising – such patients were 
older and had more impaired LVEF than those who did not fulfil the NICE criteria. However, Cubbon 
et al also clearly show that within their study population, the absolute risk of SCD was heavily 
influenced by the presence of diabetes mellitus and ischaemic heart disease – so the event rates in 
patients with diabetes (or ischaemic heart disease) not meeting the specific TA314 criteria (due to a 
narrow QRS complex) were similar to patients without diabetes (or ischaemic heart disease) who 
did. This highlights a flaw in the NICE guidance – although the recommended approach works well to 
identify patients at high relative risk of SCD, it does not provide a precise estimate of an individual’s 
absolute risk, and presumably, therefore, the likely absolute benefit. If the absolute benefit is not 
considered then not only may the physician and patient have an unrealistic estimate of the potential 
benefit of ICD technology, but NHS resources may be used inappropriately.  
The ‘blind’ application of Table 1 from the guideline could lead to an oversimplified approach with 
the risk of over-treatment of some patients, and under-treatment of others, and marked variation 
from one centre to another. TA314 recognises this, with the Appraisal Committee stating that  
“careful, explicit and shared decision-making about appropriate use of these technologies…is 
important” although “preventing sudden cardiac death....is challenging….and there is currently no 
optimal strategy for risk stratification”.
1
 Marrying detailed IPD meta-analysis from the clinical trials, 
with real world data relating to the background level of risk, is not easy nor is it easy to 
communicate the risks and benefits in an appropriate way to patients who may not know what 
questions to ask. Cubbon’s work suggests that patients with HFREF seen in a NHS cardiology clinic 
have an annual risk of sudden cardiac death, despite optimal medical therapy, that is substantial - 
around 2% - so ensuring risk stratification takes place is vital. 
It is now widely recognised that patients should be active partners in decisions about their 
healthcare. Despite considerable support from NICE and other professional bodies for such shared 
decision making,
4
 NHS surveys consistently report that at least 40% of patients want to be more 
involved in decisions about their care, and 20% report that they were given insufficient information 
about their treatment.
5
 Key questions include: What are my options? What are the benefits and 
possible harms? How likely are these? The new NICE guidance on ICDs goes some way in helping 
clinicians to use the evidence-base to determine (and discuss) the best option for the individual 
patient, but much further work is needed before we are in the situation where advice can be 
accurately tailored to the individual, and where shared decisions can be meaningfully made.  
What is clear is that the implementation of TA314 should lead to an increase in the implant rate for 
‘high energy’ devices. Of the 1000 or so patients with HF seen in the outpatient clinics by Cubbon et 
al, at least 30% (and perhaps as high as 60% depending on how ‘high risk’ is defined in those with a 
QRS duration < 120 ms) of patients are potentially eligible for an ICD. Similar reports have appeared 
from other centres.
6
 Currently, English implant rates are well below the Western European average, 
but the rates appear to be steadily increasing despite major financial strains on the NHS.
7
  The 
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official NICE assessment of the cost implications of implementing TA314 in England was £19m in the 
first year, and £33m in the second and subsequent years, although it accepted that implant rates 
varied ‘considerably’ across the country.
8
 Such variation is something that NICE is charged with 
reducing.  
Ensuring shared decision making based on best available trial data combined with real-life evidence 
and clinical expertise is a tall order, but something that all stakeholders should pursue without delay. 
Only then will there be more equitable implementation of the guidance and a reduction in the huge 
variation in practice seen across the UK in the identification of patients with HFREF for whom an ICD 
may be appropriate as part of a strategy to reduce the risk of sudden cardiac death.   
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From TA314 (reference 1). 
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